Guidance For Drugs To Target Early Alzheimer’s Notes Lack Of Metrics, Biomarkers

FDA’s new draft guidance on developing drugs to treat people in the early stages of Alzheimer’s disease, before any noticeable dementia sets in, is sure to generate further discussion and comment on how best to identify and measure the disease and its progression.